These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2946878)

  • 1. Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation.
    Yamauchi K; Furui H; Taniguchi N; Sotobata I
    Jpn Heart J; 1986 Jul; 27(4):481-7. PubMed ID: 2946878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter.
    Sakurai K; Hirai T; Nakagawa K; Kameyama T; Nozawa T; Asanoi H; Inoue H
    Chest; 2003 Nov; 124(5):1670-4. PubMed ID: 14605033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity in patients with atrial fibrillation.
    Furui H; Taniguchi N; Yamauchi K; Sotobata I; Saito H; Inagaki H
    Jpn Heart J; 1987 Mar; 28(2):177-84. PubMed ID: 3599409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
    Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
    Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study.
    Melgaard L; Jensen M; Overvad TF; Larsen TB; Lip GYH; Nielsen PB
    Int J Clin Pract; 2020 Oct; 74(10):e13589. PubMed ID: 32574395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
    Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma beta-thromboglobulin and platelet factor 4 in patients with chronic renal failure and effect of hemodialysis.
    Endo Y; Mamiya S; Satoh M; Takahashi K; Harada T
    Tohoku J Exp Med; 1981 Dec; 135(4):349-58. PubMed ID: 6175048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.
    Cella G; Colby SI; Taylor AD; McCracken L; Parisi AF; Sasahara AA
    Thromb Res; 1983 Mar; 29(5):499-509. PubMed ID: 6222505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.
    Kamath S; Blann AD; Caine GJ; Gurney D; Chin BS; Lip GY
    Stroke; 2002 May; 33(5):1237-42. PubMed ID: 11988597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of potential roles of combinatorial microRNA regulation in occurrence of valvular heart disease with atrial fibrillation based on computational evidences.
    Wang G; Rao N; Liu D; Jiang H; Liu K; Yang F; Chen Y; Huang K
    PLoS One; 2019; 14(9):e0221900. PubMed ID: 31479479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.
    Lip GY; Lip PL; Zarifis J; Watson RD; Bareford D; Lowe GD; Beevers DG
    Circulation; 1996 Aug; 94(3):425-31. PubMed ID: 8759084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia.
    Atalar E; Haznedaroglu IC; Acil T; Ozer N; Kilic H; Ovunc K; Aksoyek S; Nazli N; Kes S; Kabakçi G; Kirazli S; Ozmen F
    Platelets; 2003; 14(7-8):407-11. PubMed ID: 14713509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; de Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B
    Thromb Haemost; 2017 Dec; 117(12):2215-2236. PubMed ID: 29212110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man.
    Lamirault G; Gaborit N; Le Meur N; Chevalier C; Lande G; Demolombe S; Escande D; Nattel S; Léger JJ; Steenman M
    J Mol Cell Cardiol; 2006 Jan; 40(1):173-84. PubMed ID: 16242148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atrioventricular asynchrony on platelet activation: implication of thromboembolism in paced patients.
    Lau CP; Tse HF; Cheng G
    Heart; 1997 Oct; 78(4):358-63. PubMed ID: 9404251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-dimer level influences thromboembolic events in patients with atrial fibrillation.
    Nozawa T; Inoue H; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2006 Apr; 109(1):59-65. PubMed ID: 15992948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease.
    Cooley N; Cowley MJ; Lin RC; Marasco S; Wong C; Kaye DM; Dart AM; Woodcock EA
    Physiol Genomics; 2012 Feb; 44(3):211-9. PubMed ID: 22147268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aortic spontaneous echocardiographic contrast and hemostatic markers in patients with nonrheumatic atrial fibrillation.
    Nakagawa K; Hirai T; Shinokawa N; Takashima S; Nozawa T; Asanoi H; Inoue H
    Chest; 2002 Feb; 121(2):500-5. PubMed ID: 11834664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.